Intermittent nesiritide therapy in outpatients with chronic heart failure
Heart failure (HF) continues to be a significant health problem in the United States. Nearly 550,000 people are diagnosed annually with this condition, and HF is responsible for over 1 million hospitalizations per year.1,2 Despite advances in pharmacologic therapy, a small percentage of patients wit...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | article |
| منشور في: |
2005
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/3932 https://doi.org/10.1093/ajhp/62.2.196 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/62/2/196/5135612 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513462513696768 |
|---|---|
| author | Sheikh-Taha, Marwan |
| author_facet | Sheikh-Taha, Marwan |
| author_role | author |
| dc.creator.none.fl_str_mv | Sheikh-Taha, Marwan |
| dc.date.none.fl_str_mv | 2005 2016-06-02T11:05:33Z 2016-06-02T11:05:33Z 2016-06-02 |
| dc.identifier.none.fl_str_mv | 1079-2082 http://hdl.handle.net/10725/3932 https://doi.org/10.1093/ajhp/62.2.196 Sheikh-Taha, M. (2005). Intermittent nesiritide therapy in outpatients with chronic heart failure. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 62(2), 196-198. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/62/2/196/5135612 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | American Journal of Health-System Pharmacy |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Heart failure (HF) continues to be a significant health problem in the United States. Nearly 550,000 people are diagnosed annually with this condition, and HF is responsible for over 1 million hospitalizations per year.1,2 Despite advances in pharmacologic therapy, a small percentage of patients with severe HF remain refractory to maximum medical therapy. In addition, these patients have high mortality rates, a poor quality of life, and frequent hospitalizations with elevated health care costs. For this subset of patients, some centers in the United States continue to use periodic ino-tropic therapy on an inpatient or outpatient basis under the rationale of reducing symptoms, hospitalizations, and medical costs, even at the risk of increased mortality. Nesiritide, a human B-type natriuretic peptide, is the first of a new class of agents for the treatment of decompensated HF. In... |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_87751fdb981a013248a045bd7f291bc5 |
| identifier_str_mv | 1079-2082 Sheikh-Taha, M. (2005). Intermittent nesiritide therapy in outpatients with chronic heart failure. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 62(2), 196-198. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/3932 |
| publishDate | 2005 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Intermittent nesiritide therapy in outpatients with chronic heart failureSheikh-Taha, MarwanHeart failure (HF) continues to be a significant health problem in the United States. Nearly 550,000 people are diagnosed annually with this condition, and HF is responsible for over 1 million hospitalizations per year.1,2 Despite advances in pharmacologic therapy, a small percentage of patients with severe HF remain refractory to maximum medical therapy. In addition, these patients have high mortality rates, a poor quality of life, and frequent hospitalizations with elevated health care costs. For this subset of patients, some centers in the United States continue to use periodic ino-tropic therapy on an inpatient or outpatient basis under the rationale of reducing symptoms, hospitalizations, and medical costs, even at the risk of increased mortality. Nesiritide, a human B-type natriuretic peptide, is the first of a new class of agents for the treatment of decompensated HF. In...PublishedN/A2016-06-02T11:05:33Z2016-06-02T11:05:33Z20052016-06-02Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1079-2082http://hdl.handle.net/10725/3932https://doi.org/10.1093/ajhp/62.2.196Sheikh-Taha, M. (2005). Intermittent nesiritide therapy in outpatients with chronic heart failure. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 62(2), 196-198.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://academic.oup.com/ajhp/article-abstract/62/2/196/5135612enAmerican Journal of Health-System Pharmacyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/39322021-03-19T10:00:49Z |
| spellingShingle | Intermittent nesiritide therapy in outpatients with chronic heart failure Sheikh-Taha, Marwan |
| status_str | publishedVersion |
| title | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| title_full | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| title_fullStr | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| title_full_unstemmed | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| title_short | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| title_sort | Intermittent nesiritide therapy in outpatients with chronic heart failure |
| url | http://hdl.handle.net/10725/3932 https://doi.org/10.1093/ajhp/62.2.196 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/62/2/196/5135612 |